In a report released today, Jonathan Block from Stifel Nicolaus reiterated a Buy rating on Align Tech. (NASDAQ: ALGN), with a price target of $70. The company’s shares closed yesterday at $56.01.
Currently, the analyst consensus on Align Tech. is Strong Buy and the average price target is $71.50, representing a 27.7% upside. In a report issued on April 21, Morgan Stanley also upgraded the stock to Buy with a $79 price target.
Based on Align Tech.`s latest earnings report from December 31, the company posted quarterly revenue of $198.6M and quarterly net profit of $39.54M. In comparison, last year the company earned revenue of $180.6M and had a net profit of $32.44M.
Financial bloggers on sites such as zacks.com, investorplace.com and others, seem to have Positive view on ALGN. When evaluating the opinions of financial bloggers over the last 3 months, 66% of bloggers have indicated a Bullish sentiment, while 34% have indicated a Bearish sentiment. The average blogger Bullish sentiment in the Healthcare sector is 66% which is slightly more positive than the blogger sentiment of ALGN.
Unlike Stifel Nicolaus` latest rating, based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is neutral on the stock. Most recently, in February 2015, Raphael Pascaud, a VP, International at ALGN sold 6,500 shares for a total of $366,535.
According to TipRanks.com, Block is a 4-star analyst with an average return of 18.2% and a 77.1% success rate. Block covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Zeltiq Aesthetics, and Sirona Dental.
Align Technology Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM digital services used in dentistry, orthodontics, and dental records storage.